ReviewCardiovascular diabetology2019
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
Open access · goldAbstract readReviewConsensus Statement
In one paragraph
Review in Cardiovascular diabetology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 141 citations in OpenAlex.
- Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study.Journal of atherosclerosis and thrombosis · 2025Trial
- Prospective randomized comparative study of the effect of pemafibrate add-on or double statin dose on small dense low-density lipoprotein-cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy.Journal of diabetes investigation · 2023Trial
- Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab.European journal of preventive cardiology · 2020Trial
- Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.Cardiovascular diabetology · 2020Trial
- Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities.Biomedicines · 2026Review
- Molecular Mechanisms and Clinical Evidence Supporting the Four Pillars of Therapy in Diabetic Kidney Disease: Emerging Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Genomic and clinical predictors of cardiovascular disease in Familial dyslipidemia: risk stratification in Egyptian adolescents and young adults.Lipids in health and disease · 2025Article
- Diagnosing and treating fatty liver disease: strategies for hepatocellular carcinoma and cardiovascular disease prevention.Clinical and experimental hepatology · 2025Article
- Long-Term Safety and Efficacy of Pemafibrate to Treat Hyperlipidemia: Post-marketing Surveillance Over a 24-Month Observation Period in Japan.Advances in therapy · 2025Observational
- From Nuclear Receptor Regulation to Spleen Activating and Accumulation Resolving Therapy: A Review of Traditional Chinese Medicine Against Diabetes and Inflammation.International journal of molecular sciences · 2025Review
- Effect of Pemafibrate on Cerebrovascular Atherosclerosis in Patients with Stroke and Hypertriglyceridemia.Journal of atherosclerosis and thrombosis · 2025Article
- A Significant Effect of Pemafibrate on Carotid and Cerebral Atherosclerosis in Patients with Hypertriglyceridemia and Stroke.Journal of atherosclerosis and thrombosis · 2025Article
- Remnant cholesterol predicts risk of recurrent thrombosis beyond LDL-cholesterol in patients with antiphospholipid syndrome.BMC medicine · 2025Article
- The Association of Fibrate Use with Kidney Outcomes and Mortality.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?Current atherosclerosis reports · 2025Review
- The impact of remnant lipids on keloid formation: a causal analysis using mendelian randomization.Archives of dermatological research · 2025Article
- Treatment with pemafibrate ameliorates fatty liver index and atherogenic lipid profiles in Japanese patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2025Article
- Emerging role of sphingolipids and extracellular vesicles in development and therapeutics of cardiovascular diseases.International journal of cardiology. Heart & vasculature · 2024Review
- Lessons from PROMINENT and prospects for pemafibrate.Cardiovascular diabetology · 2024Article
- Identification of co-expressed genes and immune infiltration features related to the progression of atherosclerosis.Journal of applied genetics · 2024Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors at 20 institutions in 28 countries.
Jean-Charles FruchartR3i Foundation, Picassoplatz 8, 4010, Basel, Switzerland. jean-Charles.fruchart@r3i.org.
Raul D SantosHospital Israelita Albert Einstein, and Lipid Clinic, Heart Institute (InCor) University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil.
Carlos Aguilar-SalinasUnidad de Investigacion de Enfermedades Metabolicas, Department of Endocrinolgy and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Masanori AikawaCenter for Interdisciplinary Cardiovascular Sciences and Center for Excellence in Vascular Biology, Division of Cardiovascular Medicine and Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Khalid Al RasadiDepartment of Clinical Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman.
Pierre AmarencoDepartment of Neurology and Stroke Center, Paris-Diderot-Sorbonne University, Paris, France.
Philip J BarterLipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.
Richard CeskaIIIrd Dept Int. Med, Center for Preventive Cardiology, 3rd Internal Medicine Clinic, University General Hospital and Charles University, Prague, Czech Republic.
Alberto CorsiniDepartment of Pharmacological and Biomolecular Sciences, Università Degli Studi di Milano, Milan, Italy.
Jean-Pierre DesprésCentre de recherche sur les soins et les services de première ligne-Université Laval du CIUSSS de la Capitale-Nationale, Department of Kinesiology, Faculty of Medicine, Université Laval, Québec, QC, Canada.
Patrick DuriezINSERM, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, University of Lille, Faculty of Pharmacy, University of Lille, UDSL, Lille, France.
Robert H EckelDivision of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA.
Marat V EzhovLaboratory of Lipid Disorders, National Cardiology Research Center, Moscow, Russian Federation.
Michel FarnierLipid Clinic, Point Médical and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France.
Henry N GinsbergColumbia University Vagelos College of Physicians and Surgeons, New York, USA.
Michel P HermansDivision of Endocrinology and Nutrition, Cliniques Universitaires St-Luc and Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium.
Shun IshibashiDivision of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University, Shimotsuke, Japan.
Fredrik KarpeOCDEM, University of Oxford and the NIHR Oxford Biomedical Research Centre, OUH Foundation Trust, Churchill Hospital, Oxford, UK.
Tatsuhiko KodamaLaboratory for System Biology and Medicine Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Wolfgang KoenigDeutsches Herzzentrum München, Technische Universitat München, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
Michel KrempfMass Spectrometry Core facility of West Human Nutrition Research Center (CRNHO), Hotel Dieu Hospital, Nantes, France.
Soo LimDepartment of Internal Medicine, Seoul National University Bundang Hospital and Seoul National University College of Medicine, Seongnam, Republic of Korea.
Alberto J LorenzattiDAMIC Medical Institute/Rusculleda Foundation for Research, Córdoba, Argentina.
Ruth McPhersonRuddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, Canada.
Jesus Millan Nuñez-CortesInternal Medicine, Lipids Unit, Gregorio Marañón University Hospital, Madrid, Spain.
Børge G NordestgaardDepartment of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
Hisao OgawaNational Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Chris J PackardInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Jorge PlutzkyCardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Carlos I Ponte-NegrettiUnidad de Prevención Cardiometabólica Cardiocob. Servicio de Cardiología Hospital el Pino Santiago de Chile, Sociedad Inter Americana de Cardiología SIAC Chairman Cardiovascular Prevention Comite, Santiago de Chile, Chile.
Aruna PradhanDivision of Cardiovascular Medicine, VA Boston Medical Center, Boston, MA, USA.
Kausik K RayImperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK.
Željko ReinerDepartment of Internal Medicine, University Hospital Centre Zagreb, School of Medicine, Zagreb University, Kispaticeva 12, Zagreb, Croatia.
Paul M RidkerDivision of Cardiovascular Medicine and Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Massimiliano RuscicaDepartment of Pharmacological and Biomolecular Sciences, Università Degli Studi di Milano, Milan, Italy.
Shaukat SadikotDepartment of Endocrinology/Diabetology, Jaslok Hospital and Research Centre, Mumbai, India.
Hitoshi ShimanoDepartment of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki, 305-8575, Japan.
Piyamitr SritaraDepartment of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Jane K StockR3i Foundation, Picassoplatz 8, 4010, Basel, Switzerland.
Ta-Chen SuDepartments of Internal Medicine and Environmental and Occupational Medicine, National Taiwan University; Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, Taiwan.
Andrey V SusekovFaculty of Clinical Pharmacology and Therapeutics, Academy for Postgraduate Continuous Medical Education, Moscow, Russian Federation.
André TartarFaculté de Pharmacie de Lille, Lille, France.
Marja-Riitta TaskinenResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki and Clinical Research Institute, HUCH Ltd., Helsinki, Finland.
Alexander TenenbaumSackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.
Lale S TokgözoğluDepartment of Cardiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Brian TomlinsonDepartment of Medicine & Theraputics, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Anne Tybjærg-HansenDepartment of Clinical Biochemistry, Rigshospitalet; Copenhagen University Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Paul ValensiDepartment of Endocrinology, Diabetology and Nutrition, Jean-Verdier Hospital (AP-HP), Paris 13 University, Sorbonne Paris Cité, CRNH-IdF, CINFO, 93140, Bondy, France.
Michal Vrablík3rd Department of Medicine, 1st Faculty of Medicine of Charles University and General University Hospital in Prague, Prague, Czech Republic.
Walter WahliLee Kong Chian School of Medicine, Nanyang Technological University Singapore, Clinical Sciences Building, 11 Mandalay Road, Singapore, 308232, Singapore.
Gerald F WattsLipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, School of Medicine, University of Western Australia, Perth, Australia.
Shizuya YamashitaRinku General Medical Center, Izumisano, Osaka, Japan.
Koutaro YokoteDepartment of Endocrinology, Hematology and Gerontology, Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Alberto ZambonDepartment of Medicine-DIMED, University of Padua, Padua, Italy.
Peter LibbyDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Brigham and Women's Hospital · USC&A Foundation (Switzerland) · CHGeneral University Hospital in Prague · CZUniversité de Lille · FRUniversité Sorbonne Paris Nord · FRUniversity of Milan · ITBoston Medical Center · USCanadian Heart Research Centre · CAChiba University · JPChinese University of Hong Kong · HKCHU Dijon Bourgogne · FRChurchill Hospital · GBCliniques Universitaires Saint-Luc · BEColumbia University · USGerman Centre for Cardiovascular Research · DEHacettepe University · TRHarvard University · USHospital Israelita Albert Einstein · BRImperial College London · GBInstitute for Molecular Medicine Finland · FI
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.
Indexed as
AnimalsBenzoxazolesBiomarkersButyratesCardiovascular DiseasesConsensusDyslipidemiasHumansHypolipidemic AgentsLipidsMolecular Targeted TherapyPatient SafetyPPAR alphaRisk AssessmentRisk FactorsSignal TransductionBenzoxazolesBiomarkersButyratesHypolipidemic AgentsLipidsPPAR alphaPPARA protein, human(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidAtherogenic dyslipidemiaDiabetesInflammationPemafibrate (K-877)PROMINENTRemnant cholesterolResidual cardiovascular riskSelective peroxisome proliferator-activated receptor alpha modulatorSPPARMalphaTriglyceridesVisceral obesity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.